Dataset from Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background
methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence
of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background
methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended
to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function
that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also
included.